Last updated: May 27, 2026
- Takeda is the company responsible for the US product listing and commercialization of Trintellix (vortioxetine) tablets.
What manufacturing roles exist in the Trintellix supply chain?
- Finished-dose manufacturing: contract manufacturers typically handle tablet manufacture, coating, packaging, and quality release.
- API supply: contract manufacturers typically synthesize vortioxetine drug substance and supply it to the finished-dose site.
- Secondary packaging and distribution: often performed at the finished-dose site or through logistics partners tied to the product supply agreement.
What does FDA product labeling typically indicate about suppliers?
FDA drug labeling and Orange Book records usually identify the NDA holder and may identify manufacturers/labelers and submission manufacturing site(s). Patent and exclusivity records do not directly enumerate procurement suppliers for API beyond what is disclosed through FDA manufacturing disclosures.
How do you identify Trintellix suppliers from FDA records?
The most direct supplier identifiers come from:
- FDA Orange Book entries linked to the reference listed drug (RLD) status for Trintellix.
- Drugs@FDA product details (labeler and application holder).
- FDA label manufacturing/distribution statements in current packaging.
What is the FDA Orange Book status of Trintellix and what does it imply for sourcing?
Orange Book listings show whether a product is the RLD and list approved strengths, dosage forms, and patent-protected aspects. Orange Book entries do not, on their own, list all API and tablet suppliers, but they can be used to anchor the correct NDA and RLD record for cross-referencing manufacturing disclosures in the FDA database.
Orange Book listings: where to look
- Identify Trintellix RLD entry and review the NDA holder and any listed manufacturers tied to the approved product.
Why Orange Book status matters for supplier mapping
- When generic or abbreviated applications reference the RLD, FDA records may show different manufacturing sites, which can reveal which vendors are currently making finished product.
Who are the Trintellix tablet manufacturers listed on FDA product records?
This requires reading the exact Drugs@FDA labeling and product listing manufacturing/labeler fields for the active strengths and dosage forms. Those entries are the canonical source for identifying the manufacturing and labeler entities that appear in the FDA record for Trintellix tablets.
Trintellix dosage form and labeler context
- Trintellix is marketed as oral tablets (multiple strengths). Each strength can share the same NDA and labeler, but manufacturing site details can differ by packaging configuration.
Which companies supply the vortioxetine API for Trintellix?
API supplier identification is usually available only through:
- Detailed FDA CMC manufacturing disclosures and site-specific inspections data, which are not consistently present in public, easy-to-parse fields; and/or
- Supplier names appearing in publicly available parts of submissions, which are not always indexed into a single record.
Publicly usable supplier identifiers
- The API supplier role is typically contracted and not always explicitly stated in consumer-facing labeling.
- The NDA holder and the finished-dose manufacturer site(s) provide the most reliable publicly indexed supplier mapping.
What is the Trintellix contract manufacturing model (tablet vs. API)?
For branded oral small molecules like vortioxetine, common models are:
- NDA holder retains control of regulatory quality systems while contract manufacturers make the tablet under FDA cGMP.
- API is manufactured by a separate drug substance vendor and delivered to the tablet maker for formulation and tableting.
Supply chain “control points”
- Release testing and batch certification are generally at the finished-dose site that is listed for the NDA submission.
- API vendors are typically controlled by technical transfer packages and quality agreements.
What generic entry risks change the Trintellix supplier landscape?
When generic manufacturers enter, the supply network can change in two ways:
- Bi-directional sourcing: branded supply may remain with incumbent contract sites, but the market often pushes API and formulation capacity toward the higher-volume entrants.
- Regulatory disclosure changes: generic applications can reveal additional manufacturing sites that were not visible from the branded record alone.
Paragraph IV and litigation settlement impacts
- Patent litigation outcomes can affect when generics launch.
- Launch timing influences whether the API supply network shifts toward multiple competitors.
How does Trintellix compare with similar branded oral antidepressants on supply structure?
The supply pattern for small-molecule antidepressants is typically:
- One NDA holder (brand owner),
- Contract API suppliers,
- Contract finished-dose manufacturers,
- Central distribution through the brand owner.
Competitive landscape pressure
- As generics approach approval windows, branded supply chain may keep existing contract sites while adding redundancy to mitigate shortages.
Key Takeaways
- Takeda is the marketing authorization holder for Trintellix (vortioxetine) in the US.
- Publicly accessible FDA-indexed information most reliably identifies labeler and NDA holder roles, while API supplier names often require deeper CMC disclosures not fully enumerated in standard public fields.
- Supplier mapping for Trintellix is best anchored to Drugs@FDA and Orange Book records for the correct RLD/NDA entry, then expanded using the product’s listed manufacturing/labeler fields for each tablet strength.
FAQs
-
Which company owns the NDA for Trintellix in the US?
-
Are Trintellix tablet manufacturers named in FDA product listings?
- Yes, FDA product listing fields can include manufacturer/labeler information, but it must be taken from the specific Drugs@FDA and Orange Book entries tied to each Trintellix tablet strength.
-
Can API suppliers for vortioxetine be reliably identified from public labeling alone?
- Usually not; API supplier names are often not disclosed in consumer-facing labeling and may require CMC submission details.
-
Do Orange Book patents list Trintellix manufacturing suppliers?
- Orange Book primarily lists patent and exclusivity information tied to the product; manufacturing supplier identifiers are typically found in product listing/manufacturing fields, not in the patent list itself.
-
Will generic entry change who supplies Trintellix tablets?
- Trintellix branded supply may remain on existing contract manufacturing sites, but market-wide API and tablet manufacturing utilization can shift once generics scale.
References
- FDA. Drugs@FDA: Product details for Trintellix (vortioxetine). US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Orange Book: Trintellix (vortioxetine) listed drug. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
